Guinea-Bissau suspended a Trump administration-backed hepatitis B vaccine study on newborns pending an ethics review, according to the country's health minister. The AP report says the government moved after a six-person ethics committee did not meet during the initial confirmation process, raising concerns about how the research had been approved and how it should proceed.
The study design is at the center of the controversy. As described in the AP report, it is a randomized controlled trial in which some infants would receive the hepatitis B vaccine at birth and others would not. Children would then be tracked for death, illness and long-term developmental outcomes. That structure has drawn criticism because the vaccine is already known to work, and withholding it from babies at risk of infection has raised obvious ethical alarms.
The source says the research is backed by a $1.6 million no-bid contract awarded to a Danish university and funded by the U.S. Centers for Disease Control and Prevention. It also notes that one of the scientists involved has been praised by U.S. Health Secretary Robert F. Kennedy Jr. Those details explain why the project is attracting attention well beyond Guinea-Bissau: it sits at the intersection of public health, vaccine policy and political controversy.
The Africa CDC response was careful but supportive of review. Director-General Jean Kaseya said he supported the ethical review and emphasized the agency's relationship with the U.S. government. U.S. health officials, meanwhile, said the study was still set to proceed and that they were working with partners to finalize the protocols. That split shows the uncertainty around the project: one side has paused the work, while the other says it is continuing.
The AP report also provides important scale. The researchers were funded for five years to study 14,000 newborns, with the first 500 followed for five years to look for behavior and brain development problems. Those numbers show that this is not a small pilot but a major research program, which makes the ethics review even more consequential.
What makes the story especially sensitive is that the scientific consensus is already strong on the basic question of whether newborn hepatitis B vaccination protects children. The issue is not whether the vaccine works in general. It is whether a study should withhold it from some newborns in order to observe outcomes in a region where infection is common. That is why the ethics review is now the central development.
The split between the Guinean-Bissau suspension and the U.S. position makes the case especially delicate. A pause for ethics review does not automatically end the study, but it does force public officials to confront whether consent, oversight and risk are adequate for a trial involving newborns. The AP report also notes that the team planned to follow the first 500 enrolled children for five years, which shows how long the consequences of the design could linger. That is why the ethics committee gap became the decisive issue: in a study this sensitive, process is part of the substance.
